A Phase IIa, Double-Blind, Randomised, Placebo-controlled, Exploratory Study to Evaluate the Safety, Biological Activity and Pharmacokinetics of GBR 830 in Adult Patients With Moderate-to-Severe Atopic Dermatitis
Phase of Trial: Phase II
Latest Information Update: 16 Feb 2018
At a glance
- Drugs GBR 830 (Primary)
- Indications Atopic dermatitis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Glenmark Pharmaceuticals S.A.
- 16 Feb 2018 Results presented in a Glenmark Pharmaceuticals media release.
- 16 Feb 2018 According to a Glenmark Pharmaceuticals media release, data was presented at the 2018 American Academy of Dermatology (AAD) Annual Meeting.
- 04 Aug 2017 Status changed from recruiting to completed.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History